Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
Executive Summary
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology
You may also be interested in...
Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009
Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009
Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry’s strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA’s novel approvals in 2009.